

5.1.2e)

Van: 5.1.2e)
Verzonden: woensdag 3 maart 2021 16:36
Aan: 5.1.5
CC: 5.1.2e); 5.1.2e); dienstpostbussecretariaatPDC19@minvws.nl; 5.1.2e); 5.1.2e); 5.1.2e)

Onderwerp: FW: Thank you by Pfizer/BioNTech and Our Commitment to the Netherlands

Beste collega digitale balie,

Graag onderstaande mail innemen en doorzetten naar de PD Covid-19.

Groet,

5.1.2e

Met vriendelijke groet,

5.1.2e
5.1.2e

Ministerie van Volksgezondheid, Welzijn en Sport | Directie Bestuurlijk en Politieke Zaken |

Parnassusplein 5 | 2500 EJ | Den Haag | Postbus 20350 | 2500 EJ | Den Haag |

 5.1.2e |  5.1.2e |  5.1.2e@minvws.nl | www.rijksoverheid.nl

Bij VWS geldt een legitimatieplicht voor de toegang tot het ministerie. Dit betekent dat bij uw bezoek aan VWS om geldige legitimatie wordt gevraagd voor u het pand verder kunt betreden. Graag vraag ik uw aandacht hiervoor. Alvast bedankt voor de medewerking

Van: 5.1.2e <5.1.2e@Pfizer.com>

Verzonden: woensdag 3 maart 2021 13:00

Aan: Jonge, H.M. de (Hugo) <5.1.2e@minvws.nl>; Minister van VWS <5.1.2e@minvws.nl>

Onderwerp: Thank you by Pfizer/BioNTech and Our Commitment to the Netherlands

Dear Minister De Jonge,

First of all, I would like to thank and compliment you for your, and your team's, relentless efforts during these challenging times. Thank you for keeping the good spirits and a steady eye on the finish line, ending the pandemic. Thank you for your recognition of Pfizer/BioNTech regarding our commitment to significantly increase our COVID19 vaccine deliveries to the Netherlands. As we shared with RIVM and your Ministry of Health yesterday afternoon, April onwards we plan to ship 5.1.1c doses per week, from current levels of 5.1.1c doses per week in March. This is fully aligned with our commitment to deliver 5.1.1c doses in the second quarter of 2021 to the Netherlands. Additionally, I would like to share with you that we are in regular touch with RIVM and your Ministry to address any queries they may have and support them anytime.

Furthermore, thank you for your appointment of a special Vaccines Envoy. We are very encouraged with this development and had a very productive dialogue with 5.1.2e last week and discussed different avenues for collaboration and mutual interest for future. Additionally, we are in regular touch with various stakeholders to ensure we provide timely update and relevant information, and address any questions. We very much appreciate the open and constructive nature of these conversations.

Based on results from in-vitro studies and real world evidence, we can share that based on neutralizing antibody levels, we do not expect a significant reduction in protection provided by two doses of our COVID19 vaccine. Despite this, we are taking multiple steps to be prepared in case a strain becomes resistant. Firstly we are evaluating the effectiveness of a "booster" third dose against evolving variants. Secondly, discussions with

regulatory authorities are ongoing regarding an registration-enabling study using a variant genetic sequence, which would provide a flexible solution to rapidly adapt the vaccine for use against the B.1.351 lineage or other escape strains that may emerge. Additionally, we will continue the development of our mRNA vaccine to evaluate the dosing, efficacy and safety in immunocompromised populations, pregnant women and other high risk individuals as well as the under 16 years of age population. Lastly, we are working to improve the storage conditions of our vaccine to help aid particularly the logistical aspects. We will continue keeping you, your Ministry of Health and RIVM updated regarding these developments.

We are happy to be part of the solution to overcome the crisis of our generation. You can count on us and on our unwavering commitment. Shall you wish so, I am more than happy to have a dialogue anytime with you and answer your questions you might have.

I look forward to hearing from you.

Best wishes,


5.1.2e

5.1.2e

Pfizer Netherlands

O: 5.1.2e M: 5.1.2e

E: 5.1.2e @pfizer.com



De inhoud van dit bericht en van eventuele bijlagen is uitsluitend bedoeld voor de geadresseerde(n). Het bericht bevat informatie die confidencieel van aard en/of geprivilegieerd kan zijn. Wanneer u noch de bevoegde ontvanger, noch bevoegd bent namens deze te ontvangen, is het u niet toegestaan dit bericht te kopiëren, te gebruiken of te openbaren aan andere personen. Indien u dit bericht abusievelijk hebt ontvangen verzoeken wij u vriendelijk dit per omgaande aan de afzender te laten weten en vervolgens het bericht te vernietigen.

Pfizer bv, statutair gevestigd te Rotterdam (adres: Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, handelsregisternummer 34087728).

The content of this e-mail and of its possible attachments is intended for the named addressee(s) only. It contains information which may be confidential and which may also be privileged. Unless you are the named addressee or authorised to receive for the addressee you may not copy or use it, or disclose the e-mail or its content to anyone else. If you receive this e-mail in error please notify the originator immediately and then destroy it.